BridgeBio's heart 病気 麻薬 会合，会うs late-行う／開催する／段階 熟考する／考慮する goal, 株 急に上がる
By Khushi Mandowara
July 17 (Reuters) - BridgeBio Pharma Inc's 実験の 麻薬 for a rare heart 病気 showed 重要な 改良 in 患者s in a late-行う／開催する／段階 熟考する／考慮する, sending its 株 殺到するing 65% on Monday.
The 麻薬, acoramidis, is 存在 developed to 扱う／治療する transthyretin amyloid cardiomyopathy in which 異常な deposits of a protein called amyloid 増強 in the heart, and can 原因（となる） heart 失敗.
The 麻薬 is 推定する／予想するd to compete with Alnylam 製薬のs' patisiran, which is under regulatory review for cardiomyopathy, and Pfizer's Vyndamax, or tafamidis, already 認可するd in the U.S for the 条件.
Patisiran and tafamidis have received the nod for 扱う／治療するing another symptom of the 病気 called polyneuropathy.
In the 裁判，公判, acoramidis was 1.8 times better than placebo when 手段d for 妨げるing death, 入院 and 改良 in 6 minutes walking distance.
BridgeBio's 麻薬 改善するd 生き残り by 81% in the 熟考する／考慮する 患者s compared to 74% on the placebo, and also 減ずるd frequency of heart 病気-関係のある 入院 by 50%.
The California-based company also 供給するd 付加 data comparing it with Pfizer's 麻薬. Acoramidis showed 92% 改良 on heart 失敗 実験（する）, compared to 患者s on placebo and Pfizer's 麻薬 at 30 months.
The 付加 data 示唆するs that BridgeBio's 麻薬 was better than tafamidis in controlling the 病気, said TD Cowen 分析家 Tyler 先頭 Buren.
However, the company said 有効性 of the two 麻薬s cannot be 直接／まっすぐに compared as that was not the goal of the 裁判，公判.
Data from BridgeBio's 麻薬 also "bodes 井戸／弁護士席" for other companies developing 類似の t reatments such as Alnylam and Ionis 製薬の, RBC 資本／首都 Markets 分析家 Luca Issi said.
BridgeBio 計画（する）s to 服従させる／提出する the data to the U.S. Food and 麻薬 行政 (FDA) by the end of 2023 as part of its marketing 使用／適用. The company also 推定する／予想するs to とじ込み／提出する in 付加 markets next year.
BridgeBio's 株 were 貿易（する）ing at $30, while Alnylam's 在庫／株 rose 10.5% to $217.9.
(報告（する）／憶測ing by Khushi Mandowara in Bengaluru; Editing by Nivedita Bhattacharjee and Sriraj Kalluvila)
